Table 1 Clinical and demographic characteristics.
AN-FEP | HC | Statistics | |
|---|---|---|---|
Number of participants: N (F/M) | 29 (19/10) | 31 (20/11) | X2 = 0.007, p = 0.94 |
Number of participants, follow-up, N | 27 | 30 | |
Age ± SD, years | 21.9 ± 3.5 | 22.2 ± 3.5 | T(58) = −0.33, P = 0.74 |
Parental socioeconomic status (high/moderate/low) | 7/18/4 | 10/19/2 | Fisher’s P=0.63 |
Education ± SD, years | 12.5 ± 2.2 | 14.3 ± 2.6 | T(58) = −2.89, P = 0.005 |
Ethnicity (n) White/Asian/Middle east | 26/2/1 | 31/0/0 | |
Duration of untreated psychosis, Median (25–75th percentile) in weeks | 25.0 (12.0 – 52.0) | ||
Current tobacco use, yes/no | 13/16 | 5/26 | X2 = 5.88, P = 0.02 |
Current cannabis use, yes/no | 2/27 | 1/30 | Fisher’s P = 0.61 |
Symptoms at baseline | |||
PANSS Positive, mean ± SD | 19.6 ± 3.4 | NA | |
PANSS Negative, mean ± SD | 20.8 ± 5.1 | NA | |
PANSS General, mean ± SD | 37.5 ± 6.2 | NA | |
PANSS Total, mean ± SD | 78.2 ± 11.5 | NA | |
Symptoms after six weeks | |||
PANSS Positive, mean ± SD | 13.9 ± 3.6 | NA | T(26) = 86.5, P < 0.001a |
PANSS Negative, mean ± SD | 16.4 ± 5.2 | NA | T(26) = 33.0, P < 0.001a |
PANSS General, mean ± SD | 29.2 ± 7.4 | NA | T(26) = 38.6, P < 0.001a |
PANSS Total, mean ± SD | 59.6 ± 12.8 | NA | T(26) = 86.0, P < 0.001a |
Aripiprazole mean dose at six weeks ± SD | 9.4 ± 3.7 | NA | |
Serum-Aripiprazole level at six weeks in µg/L ± SD | 124.2 ± 66.8 | NA | |
